# Basecamp Research

> AI-native drug discovery company using biological data gathered from global biodiversity.

## Why it is interesting

Its Series C moves a data-platform thesis toward preclinical cell-therapy programs, where biological validation and clinical execution become the key risks.

## Profile

- **Latest funding:** Series C — $140M (September 23, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $140M
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-25

## Key facts

- Latest financing: $140M (Series C)

## Funding history

- Series C · $140M · September 23, 2026
  Source: https://www.basecamp-research.com/news-research/basecamp-research-raises-140m-to-advance-ai-designed-therapeutics

## Related articles

- https://venturecapitaltracker.com/2026-basecamp-research-140m-series-c-ai-therapeutics

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 25, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/basecamp-research